<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704688</url>
  </required_header>
  <id_info>
    <org_study_id>17-297</org_study_id>
    <nct_id>NCT03704688</nct_id>
  </id_info>
  <brief_title>Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of the combination of ponatinib and
      trametinib as well as the most appropriate dosages of the combination.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 9, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of Ponatinib and Trametinib</measure>
    <time_frame>maximum of 18 months</time_frame>
    <description>In the Phase I portion of the study, a standard 3+3 design will be used to find the maximum tolerated dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>In the Phase II portion of the study, RECIST criteria 1.1 will evaluate the overall response rate.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>KRAS Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Phase I: Dose Level -3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib 0.5mg PO q daily Ponatinib 15mg PO q daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Dose Level -2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib 1.0 mg PO q daily Ponatinib 15mg PO q daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Dose Level -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib 1.5 mg PO q daily 15mg PO q daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib 2 mg PO q daily Ponatinib 15mg PO q daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib 2 mg PO q daily Ponatinib 30mg PO q daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum tolerated dose as established in Phase I portion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib 0.5 mg</intervention_name>
    <description>0.5mg PO q daily</description>
    <arm_group_label>Phase I: Dose Level -3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib 1 MG</intervention_name>
    <description>1.0 mg PO q daily</description>
    <arm_group_label>Phase I: Dose Level -2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib 1.5 MG</intervention_name>
    <description>1.5mg PO q daily</description>
    <arm_group_label>Phase I: Dose Level -1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib 2 mg</intervention_name>
    <description>2 mg PO q daily</description>
    <arm_group_label>Phase I: Dose Level 1</arm_group_label>
    <arm_group_label>Phase I: Dose Level 2</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib 15 MG</intervention_name>
    <description>15mg PO q daily</description>
    <arm_group_label>Phase I: Dose Level -1</arm_group_label>
    <arm_group_label>Phase I: Dose Level -2</arm_group_label>
    <arm_group_label>Phase I: Dose Level -3</arm_group_label>
    <arm_group_label>Phase I: Dose Level 1</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib 30 MG</intervention_name>
    <description>30mg PO q daily</description>
    <arm_group_label>Phase I: Dose Level 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven diagnosis of advanced lung adenocarcinoma

          -  KRAS mutation

          -  Radiographic progression following prior treatment with platinum doublet chemotherapy
             and prior treatment with a PD-1/L1 inhibitor. Patients who are deemed not eligible for
             therapy with a PD-1/L1 inhibitor by their treating physician will also be eligible.

          -  Able to take oral medications

          -  Measurable disease as per RECIST 1.1. Previously irradiated sites of tumor may be
             considered measurable if there is radiographic progression at the site subsequent to
             the time of completing radiation.

          -  Karnofsky performance status (KPS) ≥ 70%

          -  Age &gt;18 years old

          -  Adequate organ function:

               -  AST, ALT ≤ 2.5 x ULN - Total bilirubin ≤ 1.5 x ULN -Albumin ≥ 2.5g/dL

               -  Creatinine &lt; 1.5 x ULN OR calculated creatinine clearance ≥ 50mL/min

               -  Absolute neutrophil count (ANC) ≥ 1,200 cells/mm^3

               -  Hemoglobin ≥ 9.0 g/dL

               -  Platelets ≥ 100,000/mm^3

               -  Amylase and lipase within normal limits (amylase ≤ 100, lipase ≤ 78)

          -  Female patients who:

               -  Are postmenopausal for at least 1 year before the screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, agree to practice 2 effective methods of
                  contraception, at the same time, from the time of signing the informed consent
                  through 30 days after the last dose of study drug, or agree to completely abstain
                  from heterosexual intercourse

          -  Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:

               -  Agree to practice effective barrier contraception during the entire study
                  treatment period and through 30 days after the last dose of study drug, or

               -  Agree to completely abstain from heterosexual intercourse

        Exclusion Criteria:

          -  Patients with symptomatic brain metastasis requiring escalating doses of steroids

          -  Patients with grade 2 or greater diarrhea prior to study initiation despite maximal
             medical management

          -  History of acute pancreatitis within 1 year of study entry or history of chronic
             pancreatitis

          -  History of or ongoing alcohol abuse that, in the opinion of the Investigator, would
             compromise compliance or impart excess risks associated with study participation.

          -  Pregnant or lactating women

          -  Any type of systemic therapy (chemotherapy or experimental drugs) within 2 weeks of
             starting treatment on protocol

          -  Patients who have received prior treatment with MEK inhibitor

          -  A history of clinically significant interstitial lung disease or pneumonitis

          -  Significant uncontrolled or active cardiovascular disease, specifically including, but
             not restricted to: History of clinically significant (as determined by the treating
             physician) atrial arrhythmia; or any ventricular arrhythmia, History of congenital
             long QT syndrome., Abnormal QTc (≥ 450 msec in males and ≥ 470 msec in females),
             Ejection fraction ≤ 50% as assessed by echocardiogram.

          -  History of arterial thrombotic disease, specifically including, but not restricted to:
             Myocardial infarction or unstable angina, cerebrovascular event (CVA) or transient
             ischemic attack (TIA), Peripheral vascular disease or claudication.

          -  Uncontrolled hypertension (Diastolic blood pressure &gt; 100 mmHg; Systolic blood
             pressure &gt; 150 mmHg).

          -  History of venous thromboembolism (e.g. deep venous thrombosis or pulmonary embolism)
             within 6 months of study entry. Note: Participants enrolled after this window must be
             on appropriate therapeutic anticoagulation.

          -  History of central serous retinopathy or retinal vein occlusion

          -  Patients with baseline risk factors for central serous retinopathy or retinal vein
             occlusion such as evidence of new optic disc cupping, evidence of new visual field
             defects, and intraocular pressure &gt;21 mmHg are excluded from the trial

          -  History of prior malignancy within 2 years that requires treatment. Patients who are
             considered NED from a malignancy may be considered on a case by case basis.

          -  Any other condition that, in the opinion of the investigator, may compromise the
             safety, compliance of the patient, or would preclude the patient from successful
             completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Arbour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Limited Protocol Activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Limited Protocol Activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Limited Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Limited protocol activity)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>trametinib</keyword>
  <keyword>Ponatinib</keyword>
  <keyword>KRAS Mutant Advanced Non-Small Cell Lung Cancer</keyword>
  <keyword>17-297</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

